Skip to content
AnalystLens

Merck 8-K Report, Financial Results (Aug 4, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 4, 2026
Period End
August 4, 2026
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 8-K filed August 4, 2026. Cited figures are marked; the original filing is the authoritative source.

Merck & Co. (MRK) reported second-quarter 2026 results on August 4, 2026, with worldwide sales of $16.6 billiona, up 5% (4% excluding FX).

Growth was led by KEYTRUDA/KEYTRUDA QLEX ($8.4 billionb, up 5%, including $463 million of initial KEYTRUDA QLEX sales), WINREVAIR ($588 million, up 75%), and Animal Health ($1.8 billion, up 8%). Gross margin compressed on a GAAP basis to 73.5% from 77.5%, and non-GAAP to 81.1% from 82.2%, reflecting higher amortization and inventory write-downs. The headline result was a GAAP loss of $0.54 per share and a non-GAAP loss of $0.13 per share, driven by a $2.31 per share (about $5.7 billion) one-time R&D charge for the acquisition of Terns Pharmaceuticals, which carried no tax benefit.

The full-year 2026 sales outlook was narrowed and raised to $66.3c-$67.3 billion from $65.8-$67.0 billion. Non-GAAP EPS guidance, however, fell sharply to $2.66-$2.76 from $5.04-$5.16. That reduction reflects one-time charges of $3.62 per share for the Cidara acquisition and $2.31 per share for Terns, plus about $0.12 per share of financing and MK-4208 advancement costs.

The non-GAAP effective tax rate guidance rose to 35.0%-36.0% from 23.5%-24.5%, because the acquisition charges are not tax-deductible. Non-GAAP operating expenses are now guided to $42.0d-$42.7 billion, up from $36.0-$36.8 billion, largely due to these one-time R&D charges. Pipeline news was substantial.

The FDA approved LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, and several KEYTRUDA combination approvals were granted. The company also announced positive Phase 3 TroFuse-005 data for sac-TMT in endometrial cancer and positive ATLAS-UC data for tulisokibart, while the tulisokibart SSc-ILD study failed its primary endpoint and will be discontinued. Investors should weigh strong top-line and launch momentum against the sharp near-term EPS reset, the continued KEYTRUDA patent-cycle transition, and the ongoing cost of business development.

Key Highlights

  1. Q2 2026 sales of $16.6 billion grew 5% (4% ex-FX), with KEYTRUDA/KEYTRUDA QLEX at $8.4 billion (+5%) and KEYTRUDA QLEX contributing $463 million in early uptake.
  2. WINREVAIR sales rose 75% to $588 million, and Animal Health grew 8% to $1.8 billion; JANUVIA/JANUMET declined 31% amid generic and competitive pressure.
  3. Q2 GAAP and non-GAAP EPS were a loss of $0.54 and $0.13, respectively, driven by a $2.31 per share charge for the Terns acquisition ($6.8 billion purchase price).
  4. FY2026 non-GAAP EPS guidance was cut to $2.66-$2.76 from $5.04-$5.16, mainly due to $3.62 per share (Cidara) and $2.31 per share (Terns) one-time charges; sales guidance was raised to $66.3-$67.3 billion.
  5. Gross margin compressed on higher intangible amortization and inventory write-downs: GAAP 73.5% (vs. 77.5%) and non-GAAP 81.1% (vs. 82.2%).
  6. FDA approved LIPFENDRA (enlicitide) and KEYTRUDA/KEYTRUDA QLEX combinations with WELIREG (ccRCC adjuvant), Padcev (MIBC), and Trodelvy (1L PD-L1+ TNBC).
  7. Phase 3 TroFuse-005 met OS and PFS endpoints for sac-TMT in endometrial cancer, while the Phase 2 tulisokibart SSc-ILD study failed its primary endpoint and will be discontinued.

Frequently Asked Questions

  1. Why is Merck reporting a loss per share in Q2 2026?

    The loss was driven by a one-time $2.31 per share charge, about $5.7 billion recorded in R&D, for the acquisition of Terns Pharmaceuticals. Because the charge was not tax-deductible, it also pushed the effective tax rate to negative levels. Excluding this and other items, non-GAAP EPS was a loss of $0.13.

  2. Did Merck change its full-year 2026 guidance?

    Yes. Sales guidance was raised and narrowed to $66.3-$67.3 billion from $65.8-$67.0 billion. Non-GAAP EPS guidance was reduced to $2.66-$2.76 from $5.04-$5.16, reflecting the Cidara ($3.62 per share) and Terns ($2.31 per share) one-time charges, along with about $0.12 per share of financing and MK-4208 costs. The non-GAAP tax rate guidance also increased to 35.0%-36.0%.

  3. Is the EPS guidance reduction a sign of weaker underlying business performance?

    Not necessarily. The reduction comes almost entirely from one-time acquisition charges (Cidara and Terns), not from operating deterioration. Underlying sales growth remained positive, and the sales outlook was raised. However, the filing indicates that operating expenses and gross margin pressure are rising, and investors should monitor how these trends develop.

  4. How is KEYTRUDA performing as it approaches patent expiration?

    KEYTRUDA/KEYTRUDA QLEX sales grew 5% to $8.4 billion in Q2, driven by earlier-stage indications such as TNBC, cervical, head and neck, and bladder cancer. The subcutaneous KEYTRUDA QLEX contributed $463 million in its early launch period. The filing does not discuss patent expiration timing, so investors should consult the 10-K for that information.

  5. What pipeline events could affect the stock going forward?

    Key events include the commercial launch of LIPFENDRA, the full presentation of tulisokibart HS Phase 2 data, the outcome of sac-TMT Phase 3 trials, and the oncology investor event on October 26, 2026, in Madrid. The discontinued tulisokibart SSc-ILD program is a negative development, and the filing does not provide a timeline for the MK-4208 regulatory path.